ANCERS-2 Clinical Study

Mitra Biotech is sponsoring a clinical trial to determine how physicians will utilize its CANscript testing platform to select therapies for real-world cancer patients.

ANCERS-2 is currently enrolling patients with the following types of advanced and metastatic tumors:

  • Epithelial Ovarian
  • Non-Small Cell Lung Cancer
  • Head and Neck
  • Triple Negative Breast
  • Colorectal

As a patient, you may qualify for our ongoing clinical study, ANCERS-2.

Learn more, and find out whether you qualify.

Visit to learn more about the study, including eligibility criteria and which sites are participating.